Aditxt Receives Nasdaq Delisting Notice, Ineligible for Standard Compliance Period Due to Prior Reverse Splits
Summary
Aditxt, Inc. received a Nasdaq delisting notice for failing to meet the minimum bid price requirement and is ineligible for the standard compliance period due to its history of reverse stock splits.
Key Events
-
Nasdaq Delisting Notice Received
On May 6, 2026, Aditxt, Inc. received a Staff Determination letter from Nasdaq, notifying the company of its intent to delist its securities from The Nasdaq Capital Market.
-
Failure to Meet Bid Price Rule
The delisting is due to the company's common stock closing below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
-
Ineligible for Compliance Period
Aditxt is not eligible for the standard 180-calendar day compliance period because it has effected multiple reverse stock splits with a cumulative ratio of 250 shares or more to one over the prior two-year period.
-
Company Plans to Appeal
The company intends to timely request a hearing before a Nasdaq Hearings Panel to appeal the determination, which will stay delisting actions through the hearing process, but there is no guarantee of success.
Analysis
Aditxt, Inc. has received a Staff Determination letter from Nasdaq, notifying the company of its intent to delist its securities. This is a critical development as the company failed to maintain the minimum $1.00 bid price. Crucially, Aditxt is not eligible for the typical 180-calendar day compliance period due to its history of multiple reverse stock splits (cumulative ratio of 250:1 or more) within the past two years. This ineligibility significantly heightens the risk of delisting, which would severely impact liquidity and investor confidence. While the company intends to appeal, there is no assurance of success. This event compounds the 'going concern' doubt previously disclosed in the company's last 10-K, indicating severe operational and financial challenges.
At the time of this filing, ADTX was trading at $0.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.5K. The 52-week trading range was $0.10 to $1,979.65. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.